extracellular-vesicles
(4)
Shelley Hartman Left Goldman Sachs to Bet on the Cell’s Tiny Messengers
After nineteen years in investment banking, Shelley Hartman traded advice for execution. At Aegle Therapeutics, she is turning an elegant piece of university science into a clinical-stage company, one painstaking milestone at a time.
The Boston Biotech Betting That Cells Don't Have to Show Up to Heal You
Aegle Therapeutics skips the stem cell transplant and ships only the message the cell was trying to send - a cell-free vesicle therapy now in human trials for one of the cruelest skin diseases in medicine.
Pearl Diagnostics, Inc.
Pearl Diagnostics is a Baltimore-based in vitro diagnostics company spun out of Johns Hopkins University that develops non-invasive urine tests to detect life-threatening lung infections. Its proprietary Smart Antibody technology identifies circulating microbial extracellular vesicles, and its lead product, the MycoMEIA Aspergillus Assay, became the first urine-based test to win FDA 510(k) clearance for aiding diagnosis of invasive aspergillosis. The company raised an $11.2M Series A in March 2026 to commercialize in the US and expand across Europe.
ONI
ONI (Oxford Nanoimaging) is an Oxford University spinout that shrank the super-resolution microscope from a room-sized, six-figure instrument into a desktop box the size of a sheet of A4 paper. Its flagship Nanoimager resolves single molecules down to 20 nm and pairs with the cloud-based CODI platform for analysis and collaboration, opening single-molecule science to labs studying everything from extracellular vesicles to lipid nanoparticles and cancer.